Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell biology. Lessons in rational drug design for protein kinases.

Science (New York, N.Y.) - 27 May 2005

Ahn Natalie G, Resing Katheryn A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Alkylation
Share to Cysteine
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Hydrophobic and Hydrophilic Interactions

Share to Models, Chemical

Share to Ribosomal Protein S6 Kinases, 90-kDa

Source

Identifiers

PMID: 15919981
DOI: 10.1126/science.1113707

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell biology. Lessons in rational drug design for protein kinases.PMID 15919981Read ↗

Kinase domain mutations in cancer: implications for small molecule drug design strategies.Semantic proximity Read ↗

Evolution and intelligent design in drug developmentSemantic proximity Read ↗

Polypharmacology is an enduring and nearly universal property of kinase inhibitorsSemantic proximity Read ↗

A structural atlas of kinases inhibited by clinically approved drugs.Semantic proximity Read ↗

Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVIDSemantic proximity Read ↗

The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.Semantic proximity Read ↗

An optimal set of inhibitors for Reverse Engineering via Kinase RegularizationSemantic proximity Read ↗

Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trialsSemantic proximity Read ↗

Will kinase inhibitors have a dark side?Semantic proximity Read ↗

Recent advances in targeting protein kinases and pseudokinases in cancer biologySemantic proximity Read ↗

Unraveling kinase signaling pathways with chemical genetic and chemical proteomic approaches.Semantic proximity Read ↗

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.